IP Library Granted Patent US 8,460,862
Granted Patent B2
US 8,460,862 · App. 12/381,560 · Granted Jun 11, 2013

Enzyme substrates for visualizing acidic organelles

Inventors: Daniel J. Coleman (Corvallis, OR); John J. Naleway (Eugene, OR)
Assignee: Marker Gene Technologies
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,460,862
App. No.
12/381,560
Granted
Jun 11, 2013
Kind
B2
Abstract

The present invention relates to the visualization of acidic organelles based upon organelle enzyme activity. The organelle substrates of the invention are specific for enzyme activity of the organelle and label these organelles, such as lysosomes, rendering them visible and easily observed. Substrates of the present invention include substrates that produce a fluorescent signal. The fluorogenic acidic organelle enzyme substrates of this invention are designed to provide high fluorescence at low pH values and are derivatized to permit membrane permeation through both outer and organelle membranes of intact cells and can be used for staining cells at very low concentrations. They can be used for monitoring enzyme activity in cells at very low concentrations and are not toxic to living cells or tissues.

Claims (39)

1. A method of detecting native enzyme activity in acidic organelles, comprising:

a) combining a sample that comprises mammalian cells with a solution comprising a substrate of the formula:

T −LINK− F ( R )−BLOCK( R ′)

wherein

T represents a targeting group that is a weakly basic amine containing moiety that partitions the substrate to the acidic organelle;

F represents a reporter moiety comprising one or more substituents R independently selected from the group consisting of hydrogen, halogen, alkyl, alkenyl, aryl, and heteroaryl;

BLOCK is a monovalent moiety adapted to be cleaved from the remainder of the substrate by action of a specific enzyme native to said acidic organelle, resulting in a visible signal at the site of enzyme reaction;

R′ is selected from the group consisting of an unsubstituted carboxylic acid

ester and an alkyoxy substituted carboxylic acid ester;

LINK has the formula —(CH2) a (CONH(CH2) b ) z , where a is an integer from 0-5, b is 1-5 and z is 1; and

b) detecting the presence of a visible signal, wherein

said sample is combined with said substrate in a concentration greater than 10 μM and less than 2 mM for a time sufficient for said native enzyme to remove BLOCK and produce said visible signal.

2. The method of claim 1 , wherein said acidic organelle is selected from the group consisting of an endosome and a lysosome.

3. The method of claim 1 , wherein said visible signal is selected from the group consisting of fluorescence, chemiluminescence and chromogenic staining.

4. The method of claim 1 , wherein said BLOCK is selected from the group consisting of: (i) a monovalent moiety derived by removal of a hydroxy group from phosphate or sulfate, (ii) a biologically compatible salt of (i); (iii) a monovalent moiety derived by removal of a hydroxy group from a carboxy group of an aliphatic, aromatic or amino acid or of a peptide; and (iv) a monovalent moiety derived by removal of an anomeric hydroxy group from a mono- or polysaccharide.

5. The method of claim 1 , wherein said, wherein F is selected from the group consisting of an anthracene, a benzphenalenone, a coumarin, a fluorescein, a naphthofluorescein, a naphthalene, a phenalenone, a pyrene, a resorufin, a dioxetane, an indole, a luminol and a rhodamine.

6. The method of claim 1 , wherein T has the formula —CR c R d —NR e R f , where

R c and R d are independently selected from the group consisting of hydrogen and an alkyl having 1-16 carbons; and

R e is alkyl and R f is an alkyl group having 1-16 carbon atoms or

N, R e and R f form a nitrogen heterocyclic ring system selected from the group consisting of morpholine, piperidine, pyrrolidine, piperazine, imidazole, oxazepine, azepine, pyrrole and an alkyl substituted nitrogen heterocyclic system with the alkyl having 1-18 carbons.

7. The method of claim 6 , wherein amine substituents R e and R f form a nitrogen heterocycle selected from the group consisting of pyrrolidine, piperidine, piperazine, morpholine, imidazole, azepine and oxazepine.

8. The method of claim 1 , wherein T has the formula —CR c R d —NR e R f , where:

a) R c and R d are independently selected from the group consisting of hydrogen and an alkyl having 1-16 carbons;

b) R e and R f are alkyl groups.

9. The method of claim 8 , where said alkyl groups R e and R f are substituted by a group selected from the group consisting of halogen, carboxamide, oxy, hydroxy, mercapto and cyano.

10. The method of claim 8 , wherein amine substituents R e and R f are independently an alkyl group having 1-6 carbons.

11. The method of claim 1 , wherein said substrate is present in a concentration greater than 10 uM and less than 500 uM.

12. The method of claim 1 , further comprising adding an additional detection reagent to said sample.

13. The method of claim 12 , wherein said additional detection reagent is selected from the group consisting of a membrane probe, a mitochondrial stain and a nucleic acid stain.

14. The method of claim 1 , wherein said step of detecting a visible signal comprises illuminating said sample with an excitation source at a wavelength greater than 350 nm and detecting a fluorescence response in said sample.

15. The method of claim 14 , wherein said sample comprises an abnormal cell mammalian.

16. The method of claim 15 wherein the presence of said visible signal is indicative of a disease state present in said cell abnormal mammalian.

17. The method of claim 14 , wherein the step of detecting a fluorescence response is performed using a an instrument selected from the group consisting of a microscope, a fluorometer, a microtiter plate reader, and a flow cytometer.

18. The method of claim 14 , further comprising sorting said mammalian cells based on the fluorescent response.

19. The method of claim 1 , wherein the presence of said visible signal is indicative of a metabolic response to drug activity in said acidic organelle.

20. A method of detecting native sulfatase activity in acidic organelles comprising

a) combining a sample that comprises mammalian cells with a solution comprising a substrate:

and

(b) detecting the presence of a visible signal, wherein said sample is combined with said substrate in a concentration greater than 10 μM and less than 2 mM for a time sufficient for said native sulfatase to remove a sulfate group from said substrate to produce said visible signal.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 1, 2020
From: COLEMAN, DANIEL J.; NALEWAY, JOHN J.
To: MARKER GENE TECHNOLOGIES, INC.
Reel/Frame 053660/0977 →
CONFIRMATORY LICENSE Recorded Mar 27, 2017
From: MARKER GENE TECHNOLOGIES
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 042097/0852 →
Continuity (1)
Related Publication 20100233744A1 · Sep 16, 2010